Rebecca A. Taub

机构：Madrigal Pharmaceuticals (United States) · ORCID：0000-0003-4509-7005

发表论文 214 篇 · 总被引 21912 次 · h-index 71

代表论文

• Health-related quality of life (HRQL) assessments in a 52-week, double-blind, randomized, placebo-controlled phase III study of resmetirom (MGL-3196) in patients with metabolic dysfunction–associated steatohepatitis (MASH) and fibrosis (2024 · Hepatology · 被引 34)
• Effects of Resmetirom on Metabolic‐Dysfunction Associated Steatohepatitis in Patients With Weight Loss and/or Diabetes Taking Glucagon‐Like Peptide‐1 Receptor Agonists and Other Diabetes Therapies: A Secondary Analysis of the MAESTRO ‐ NASH Trial (2025 · Alimentary Pharmacology & Therapeutics · 被引 25)
• SAT-263 Resmetirom treatment of a subgroup of patients with possible MetALD enrolled in MAESTRO-NASH, a phase 3 NASH/MASH serial liver biopsy study (2024 · Journal of Hepatology · 被引 13)
• LBO-002 Treatment with resmetirom for up to two years led to improvement in liver stiffness, fibrosis biomarkers, fibrosis scores and portal hypertension risk in 122 patients with compensated MASH cirrhosis (2025 · Journal of Hepatology · 被引 9)
• Improvement in health-related quality of life after treatment with resmetirom in patients with the spectrum of MASLD: From early MASH to MASH cirrhosis (2026 · Hepatology Communications · 被引 5)
• The Cholate Challenge Test Quantified Baseline Functional Heterogeneity and Improvement in Response to Resmetirom in MASH-related Child-Pugh A Cirrhosis (2025 · Gastro Hep Advances · 被引 4)